Korean J Urol.  2009 Oct;50(10):963-968.

The Association of Metabolic Syndrome and Prostate-Specific Antigen

• Yoon YE
• Lee JW
• Lee SY
• Lim KT
• Park SY
• Kim YT
• Lee TY
• Park HY

Abstract

PURPOSE
Recent studies have reported the association between metabolic syndrome and benign prostatic hyperplasia. This study was conducted to evaluate the relation between metabolic syndrome and prostate-specific antigen (PSA).
MATERIALS AND METHODS
From January 2004 to December 2007, a total of 4,115 male outpatients (aged 40 to 79 years) who visited the health care center at our medical center were examined. Eligible men were classified according to the presence or absence of metabolic syndrome and the number of components of the metabolic syndrome. The association between the sum of metabolic syndrome components and PSA level was evaluated. The association between each metabolic syndrome component and PSA level was also evaluated.
RESULTS
The PSA level of metabolic syndrome patients was lower than that of the control group (p=0.022). An increased number of metabolic syndrome components was significantly associated with a linear, decreasing trend in PSA levels (p-trend=0.040). When a Pearson's correlation was performed, only obesity was inversely associated with PSA level in the metabolic syndrome group. There was no significant factor that was related to having a PSA level greater than or equal to 2.5 ng/ml.
CONCLUSIONS
Metabolic syndrome should be considered as a factor associated with reduced PSA levels. If the patient with metabolic syndrome is obese, the PSA cutoff value should be lower than 4 ng/ml.

Keyword

Prostate-specific antigen; Metabolic syndrome X; Obesity

MeSH Terms

Delivery of Health Care
Humans
Male
Metabolic Syndrome X
Obesity
Outpatients
Prostate-Specific Antigen
Prostatic Hyperplasia
Prostate-Specific Antigen

Reference

1. Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess HA, Masumori N, et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol. 1995. 75:347–353.

2. Hammarsten J, Högstedt B. Hyperinsulinemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol. 2001. 39:151–158.

3. Sohn JC, Chang HS, Kim CI. The correlation between metabolic syndrome and the prostate volume. Korean J Urol. 2007. 48:603–607.

4. Kim JH, Shin BS, Kim JS, Hong YS. Voiding dysfunction of men is associated with metabolic syndrome. Korean J Urol. 2006. 47:257–262.

5. Kim YJ, Cho YJ, Oh JE, Jeon YS, Lee SC, Kim WJ. The association between metabolic syndrome and prostate-specific antigen levels. Int J Urol. 2008. 15:905–909.

6. Han JH, Choi NY, Bang SH, Kwon OJ, Jin YW, Myung SC, et al. Relationship between serum prostate-specific antigen levels and components of metabolic syndrome in healthy men. Urology. 2008. 72:749–754.

7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001. 285:2486–2497.

8. Reaven GM. Insulin resistance, cardiovascular disease, and the metabolic syndrome: How well do the emperor's clothes fit? Diabetes Care. 2004. 27:1011–1012.

9. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005. 28:2745–2749.

10. Lim S, Park KS, Lee HK, Cho SI. Changes in the characteristics of metabolic syndrome in Korea over the period 1998-2001 as determined by Korean National Health and Nutrition Examination Surveys. Diabetes Care. 2005. 28:1810–1812.

11. Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998. 1:157–162.

12. Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, et al. Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab. 2006. 91:2562–2568.

13. Kim YD, Yang WJ, Song YS, Park YH. Correlation between prostate volume and metabolic or anthropometric factors in male visitors to a health promotion center. Korean J Urol. 2008. 49:139–144.

14. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Salonen R, et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol. 2003. 149:601–608.

15. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004. 27:1036–1041.

16. Khaw KT, Barrett-Connor E. Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertens. 1988. 6:329–332.

17. Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men: A 13-year follow-up of former multiple risk factor intervention trial participants. Am J Epidemiol. 1997. 146:609–617.

18. Duell PB, Bierman EL. The relationship between sex hormones and high-density lipoprotein cholesterol levels in healthy adult men. Arch Intern Med. 1990. 150:2317–2320.

19. Werny DM, Saraiya M, Gregg EW. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol. 2006. 164:978–983.

20. Barrett-Connor E, Khaw KT, Yen SS. Endogenous sex hormone levels in older adult men with diabetes mellitus. Am J Epidemiol. 1990. 132:895–901.

21. Han JH, Chang IH, Ahn SH, Kwon OJ, Bang SH, Choi NY, et al. Association between serum prostate-specific antigen level, liver function tests and lipid profile in healthy men. BJU Int. 2008. 102:1097–1101.

22. Sohn JC, Lim MS, Chang HS, Park CH, Kim CI. The association of body mass index and prostate-specific antigen. Korean J Urol. 2007. 49:1121–1124.

23. Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer. 2005. 103:1092–1095.

24. Werny DM, Thompson T, Saraiya M, Freedman D, Kottiri BJ, German RR, et al. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev. 2007. 16:70–76.

25. Amatruda JM, Hochstein M, Hsu TH, Lockwood DH. Hypothalamic and pituitary dysfunction in obese males. Int J Obes. 1982. 6:183–189.

26. Eldrup E, Lindholm J, Winkel P. Plasma sex hormones and ischemic heart disease. Clin Biochem. 1987. 20:105–112.

27. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007. 298:2275–2280.

28. Catalona WJ, Ramos CG, Carvalhal GF, Yan Y. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology. 2000. 55:791–795.

29. Porter MP, Stanford JL. Obesity and the risk of prostate cancer. Prostate. 2005. 62:316–321.

30. Freedland SJ, Terris MK, Platz EA, Presti JC Jr. Body mass index as a predictor of prostate cancer: development versus detection on biopsy. Urology. 2005. 66:108–113.